Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004
Usefulness of determination of tumour markers TPA and cyfra 21.1 in follow up study after radical therapy in patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients Source: Eur Respir J 2003; 22: Suppl. 45, 251s Year: 2003
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Elevated circulating activin A levels in malignant pleural mesothelioma patients are related to cancer cachexia and poor response to platinum-based chemotherapy Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding Year: 2019
Clinical significance of CEA, NSE, CYFRA 21-1 in serum and pleural fluid for the diagnosis of malignant pleural effusion associated with primary lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004
Serum level of interleukin-6 as a prognostic factor in advanced nonsmall-cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 250s Year: 2003
The prognostic impact of stage and performance status on surgically resected non-small cell lung cancer Source: Annual Congress 2012 - Screening, diagnosis, staging and treatment strategies for lung cancer Year: 2012
Which definition of a central tumour is more predictive of occult mediastinal metastasis in nonsmall cell lung cancer patients with radiological N0 disease? Source: Eur Respir J, 53 (3) 1801508; 10.1183/13993003.01508-2018 Year: 2019
Serum carcinoembryonic antigen (CEA) level as a predictive marker for distant metastasis in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006
The elevation serum napsin A in primary lung adenocarcinoma, compared with CEA Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012
Increased serum levels of IL-18 are associated with lower survival and bone metastasis in non-small-cell lung cancer Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008
Plasma leptin levels in nonsmall cell lung carcinoma (NSCLC) patients at the time of the diagnosis Source: Eur Respir J 2001; 18: Suppl. 33, 65s Year: 2001
Role of progestrin releasing peptide (ProGRP), a serum based biomarker in early diagnosis of SCLC in cohort of high-risk patient presenting with symptoms related to lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
The diagnostic value of serum tumor markers in newly diagnosed lung cancer patients Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017
Fascin-1 overexpression predicts a poor prognosis in non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017
Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002
Identification of p-stage I NSCLC patients with high risk of recurrence and poor prognosis by tumor marker index (TMI) Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011
Clinicopathological significance and prognostic importance of circulating plasma DNA expression in advanced non-small cell lung cancer and its efficacy as a diagnostic tool Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012
Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response to therapy in NSCLC patients Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001